rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Carlsmed, Inc.

CARL · Nasdaq

Health CareMedical DevicesLeadingAI

CARL stood above a rising 150-day average in 10 of the last 30 weekly readings, including each of the last 10 weeks. It is 15.6% above that average now. Medical Devices: 29% of its 181 stocks in an uptrend (−5 points in four weeks); Health Care: 28% (−9 points in four weeks).

Statistics

Rotation
Leading
Weeks in an uptrend
10 in a row
Industry in uptrend
29% -5 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$5.3M
Officials’ trades on record
0
Institutions holding
75 (+11)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 10 of 30 weeks.

21 Apr – 20 Oct
19%29%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Medical Devices: A minority of its stocks are in an uptrend and the share has been slipping. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$52.0MNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months3
Buyers · sellers0 · 2
WhoDidSharesTraded
Jeffrey BertoliniChief Operating Officersold747at $14.395 Oct 2026filed 6 Oct 2026
Jeffrey BertoliniChief Operating Officersold243at $13.9930 Sep 2026filed 1 Oct 2026
Michael CordonnierCEO, Presidentsold197,855at $13.292 Mar 2026filed 4 Mar 2026
Presidio Management Group Xii, L.l.c.10% ownerbought200,000at $15.0024 Jul 2025filed 15 Sep 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders75+11 on the quarter
New · exited26 · 14
Reported value$59.4M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
Jupiter Topco LLCnew · filed 14 Aug 20261,251,616$13.0M+1,251,616
Parkman Healthcare Partners LLCadded · filed 14 Aug 2026597,318$6.2M+76,195+14.6%
BlackRock, Inc.added · filed 7 Aug 2026532,593$5.5M+85,701+19.2%
KCM Capital Incadded · filed 12 Aug 2026440,000$4.6M+240,000+120.0%
Pier Capital, LLCnew · filed 5 Aug 2026373,677$3.9M+373,677
MILLENNIUM MANAGEMENT LLCnew · filed 14 Aug 2026295,907$3.1M+295,907
Palumbo Wealth Management LLCnew · filed 12 Aug 2026267,298$2.8M+267,298
VANGUARD CAPITAL MANAGEMENT LLCreduced · filed 13 Aug 2026238,727$2.5M-37,404−13.5%
Schonfeld Strategic Advisors LLCreduced · filed 14 Aug 2026224,804$2.3M-58,376−20.6%
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 2026204,655$2.1M+11,482+5.9%
30 Sep 2025 – 30 Jun 2026
445974Sep 25Dec 25Mar 26Jun 26

Everyone who traded it

Jeffrey Bertolini Company insiderChief Operating Officer · last 5 Oct 20260 · 2
Richard Heppenstall Company insiderCFO, Treasurer · last 28 Sep 20260 · 0
Jonathan D. Root Company insiderDirector · last 3 Jun 20261 · 0
Kevin C. Oboyle Company insiderDirector · last 3 Jun 20260 · 0
Kevin Sidow Company insiderDirector · last 3 Jun 20261 · 0
Philip M. Young Company insiderDirector · last 3 Jun 20261 · 0
Michael Cordonnier Company insiderCEO, President · last 3 Mar 20260 · 1
Leonard M. Greenstein Company insiderCFO, Treasurer · last 28 Jan 20260 · 0
Niall Casey Company insiderChief IP Officer · last 28 Jan 20260 · 0
William Scott Durall Company insiderChief Commercial Officer · last 28 Jan 20260 · 0
B Capital Healthcare I, L.p. Company insider10% owner · last 24 Jul 20251 · 0
Casey M. Tansey Company insider10% owner · last 24 Jul 20251 · 0

Same industry

RCEL Avita MedicalLeading+108%
HTFL HeartflowLeading+59%
ATRC AtriCureLeading+52%
HAE HaemoneticsLeading+47%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202575.3%
Operating profit marginFY 2025 · to 31 Dec 2025-60.5%
Free cash flow marginFY 2025 · to 31 Dec 2025-58.6%
Return on capital employedFY 2025 · to 31 Dec 2025-26.4%
Debt to equityFY 2025 · to 31 Dec 20250.16×
Interest coverFY 2025 · to 31 Dec 2025-21.38×
Research spendFY 2025 · to 31 Dec 202533.7%
Share count trendFY 2025 · to 23 Feb 20260.5%
Cash and equivalentsFY 2025 · to 31 Dec 2025$85.8M
Free cash flowFY 2025 · to 31 Dec 2025−$29.6M

Analyst forecasts

No analyst forecasts yet.